Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Evaxion Biotech AS

Healthcare US EVAX

3.62USD
-0.13(3.47%)

Last update at 2026-06-03T17:53:00Z

Day Range

3.523.75
LowHigh

52 Week Range

1.4212.15
LowHigh

Fundamentals

  • Previous Close 3.75
  • Market Cap37.53M
  • Volume15997
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.87300M
  • Revenue TTM7.53M
  • Revenue Per Share TTM1.18
  • Gross Profit TTM 7.53M
  • Diluted EPS TTM-1.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.64137M -11.35500M -22.95027M -23.94100M -24.71000M
Minority interest - - - - -
Net income -7.73059M -10.56700M -22.15905M -23.16900M -24.53200M
Selling general administrative 6.49M 7.32M 10.08M 8.21M 6.25M
Selling and marketing expenses - - 0.02M - -
Gross profit 7.53M 3.34M 0.07M -0.57132M -0.34345M
Reconciled depreciation 0.61M 0.61M 0.61M 0.57M 0.34M
Ebit -9.26226M -10.39300M -22.23117M -25.26400M -25.83400M
Ebitda -8.64538M -9.78600M -21.61522M -22.43300M -23.79500M
Depreciation and amortization 0.62M 0.61M 0.62M 2.83M 2.04M
Non operating income net other - - - - -
Operating income -9.26226M -14.73200M -22.23117M -25.26400M -25.83400M
Other operating expenses 16.81M 18.08M 22.30M 25.26M 25.83M
Interest expense 0.88M 0.96M 0.90M 1.51M 0.92M
Tax provision -0.90800M -0.78800M -0.78600M -0.77200M -0.17800M
Interest income 0.30M 0.25M 2.34M 2.83M 2.04M
Net interest income 1.99M -0.70800M -3.01000M 1.32M 1.12M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.91078M -0.78800M -0.79122M -0.77200M -0.17800M
Total revenue 7.55M 3.34M 0.07M 0.00000M 0.00000M
Total operating expenses 16.76M 18.08M 21.69M 25.26M 25.83M
Cost of revenue - - - 0.57M 0.34M
Total other income expense net 0.62M 3.38M -0.71910M 1.32M 1.12M
Discontinued operations - - - - -
Net income from continuing ops -7.70700M -10.56700M -24.47400M -23.16900M -24.53200M
Net income applicable to common shares - - - - -24.53200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 28.41M 12.48M 12.89M -58.93700M 40.16M
Intangible assets - - - - 0.09M
Earning assets - - - - -
Other current assets 0.62M 1.85M 1.69M - 2.54M
Total liab 11.37M 14.14M 17.62M 13.72M 7.73M
Total stockholder equity 17.04M -1.65200M -4.72886M -72.65900M -50.43200M
Deferred long term liab - - - - -
Other current liab 1.52M 0.93M 3.91M 1.37M 1.03M
Common stock 15.79M 10.52M 5.90M 3.89M 3.75M
Capital stock 15.79M 10.52M 5.90M 3.89M 3.75M
Retained earnings -126.24192M -118.53868M -107.96681M -72.65900M -50.43200M
Other liab - - - - 0.15M
Good will - - - - -
Other assets - - - -77.95000M 0.19M
Cash 23.23M 5.05M 5.58M 13.18M 32.17M
Cash and equivalents - - - - -
Total current liabilities 4.26M 4.37M 7.08M 3.76M 4.32M
Current deferred revenue - - 0.00000M - -
Net debt -15.72974M 5.05M 5.29M -10.92900M -28.47600M
Short term debt 0.55M 0.47M 0.48M 0.30M 0.44M
Short long term debt 0.19M 0.16M 0.16M 0.14M 0.13M
Short long term debt total 7.50M 10.10M 10.87M 2.25M 3.69M
Other stockholder equity 120.73M 109.97M 87.45M -0.23500M -82.86900M
Property plant equipment - - - - 5.17M
Total current assets 24.90M 8.77M 8.35M 13.97M 34.70M
Long term investments - - - - -
Net tangible assets - - - - 16.55M
Short term investments - - - - -
Net receivables 1.05M 1.86M 1.07M 0.79M 1.90M
Long term debt 5.35M 8.01M 8.49M 7.86M 1.04M
Inventory - - - - -1.90100M
Accounts payable 2.19M 2.97M 2.69M 2.08M 2.85M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 6.76M -3.59500M 9.89M -3.65100M 79.11M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.18M 0.16M 0.17M 0.36M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 3.51M 3.72M 4.54M 5.04M 5.46M
Capital lease obligations 1.97M 1.93M 2.22M 2.25M 2.52M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.00300M -0.00300M -0.09300M -0.26800M -1.33000M
Change to liabilities - - - - -0.64700M
Total cashflows from investing activities -0.01404M -0.00300M - - -1.33000M
Net borrowings -0.75100M -1.13600M - - -0.28900M
Total cash from financing activities 22.48M 13.13M 10.71M 7.85M 49.80M
Change to operating activities - - - - 0.02M
Net income -7.73059M -10.56700M -22.15905M -23.16900M -24.53200M
Change in cash 17.28M 0.37M -7.60151M -18.98200M 26.33M
Begin period cash flow 5.95M 5.58M 13.18M 32.17M 5.83M
End period cash flow 23.23M 5.95M 5.58M 13.18M 32.17M
Total cash from operating activities -6.64528M -12.94000M -17.71823M -25.77400M -21.93300M
Issuance of capital stock 23.16M 16.55M 9.17M 0.43M 53.85M
Depreciation 0.62M 0.61M 0.62M 0.57M 0.34M
Other cashflows from investing activities - - - - 0.03M
Dividends paid - - - - -
Change to inventory - - 0.00000M 1.49M -1.86004M
Change to account receivables 0.18M 0.37M 1.11M -1.48683M 1.86M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.35308M -2.28500M -0.43200M 0.43M -3.76000M
Change to netincome - - - - 1.02M
Capital expenditures 0.01M 0.00000M 0.09M 0.29M 1.36M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.13742M 0.52M 1.56M -2.87700M 1.24M
Stock based compensation 0.31M 0.36M 0.48M 0.94M 1.38M
Other non cash items 0.61M -3.04400M 2.77M -0.24300M -0.17100M
Free cash flow -6.65631M -12.94000M -17.80536M -26.06600M -23.29300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EVAX
Evaxion Biotech AS		 -0.13 3.47% 3.62 - 3.57 4.99 2.20 2.88 -0.5929
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Evaxion Biotech AS

Dr. Neergaards Vej, Horsholm, Denmark, 2970

Key Executives

Name Title Year Born
Dr. Niels Iversen Moeller M.D. Co-Founder, VP of Bus. & Director 1979
Mr. Andreas Holm Mattsson Co-Founder and Chief AI & Culture Officer 1976
Dr. Birgitte Rono Ph.D. Chief Scientific Officer 1976
Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D. Chief Medical Officer 1968
Dr. Per Norlen Chief Exec. Officer 1970
Mr. Bo Lokke Karmark Chief Financial Officer 1965
Mr. Jesper Nyegaard Nissen Chief Operating Officer 1970
Dr. Jürgen Langhärig EMBA, Ph.D. Head of Bus. Devel. & Member of Advisory Board NA
Mr. Christian Kanstrup M.Sc. Chief Executive Officer 1972
Mr. Jesper Nyegaard Nissen M.Sc. Interim CFO & COO 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.